XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Mar. 31, 2023
Current assets:    
Cash and cash equivalents $ 6,670,810 $ 1,676,813
Other current assets 135,923 121,774
Total current assets 6,806,733 1,798,587
Property and equipment, net 21,857 39,086
Operating lease right-of-use assets 46,898 53,251
Investments measured at fair value 239,927 304,317
Intangible assets, net 150,415 144,881
Other assets 46,849 49,482
Total assets 7,312,679 2,389,604
Current liabilities:    
Accounts payable 35,226 37,830
Accrued expenses 122,148 167,129
Operating lease liabilities 10,477 11,693
Current portion of long-term debt (includes $26,950 and $26,940 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively) 45,706 40,720
Other current liabilities 31,342 15,076
Total current liabilities 244,899 272,448
Liability instruments measured at fair value 28,374 63,546
Operating lease liabilities, noncurrent 47,059 53,476
Long-term debt, net of current portion (includes $194,560 and $180,700 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively) 403,337 375,515
Other liabilities 4,428 17,032
Total liabilities 728,097 782,017
Commitments and contingencies (Note 11)
Shareholders' equity:    
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 804,890,910 and 760,143,393 shares issued and outstanding at December 31, 2023 and March 31, 2023, respectively 0 0
Additional paid-in capital 5,390,260 4,933,137
Retained earnings / (accumulated deficit) 727,287 (3,772,754)
Accumulated other comprehensive loss (27,784) (2,617)
Shareholders' equity attributable to Roivant Sciences Ltd. 6,089,763 1,157,766
Noncontrolling interests 494,819 449,821
Total shareholders' equity 6,584,582 1,607,587
Total liabilities and shareholders' equity $ 7,312,679 $ 2,389,604